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Aspirin in patients admitted to hospital with COVID-19 




Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. 
We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19. 
Methods In this randomised, controlled, open-label, platform trial, several possible treatments were compared with 
usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in 
Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either 
usual standard of care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-
based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28 day mortality. 
All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov 
(NCT04381936).
Findings Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 22 560 patients enrolled into the RECOVERY 
trial were eligible to be randomly allocated to aspirin. 7351 patients were randomly allocated (1:1) to receive aspirin 
and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) 
of 7541 patients allocated to usual care died within 28 days (rate ratio 0·96, 95% CI 0·89–1·04; p=0·35). Consistent 
results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter 
duration of hospitalisation (median 8 days, IQR 5 to >28, vs 9 days, IQR 5 to >28) and a higher proportion were 
discharged from hospital alive within 28 days (75% vs 74%; rate ratio 1·06, 95% CI 1·02–1·10; p=0·0062). Among 
patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion 
meeting the composite endpoint of invasive mechanical ventilation or death (21% vs 22%; risk ratio 0·96, 95% CI 
0·90–1·03; p=0·23). Aspirin use was associated with a reduction in thrombotic events (4·6% vs 5·3%; absolute 
reduction 0·6%, SE 0·4%) and an increase in major bleeding events (1·6% vs 1·0%; absolute increase 0·6%, 
SE 0·2%). 
Interpretation In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality 
or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in 
the rate of being discharged alive within 28 days.
Funding UK Research and Innovation (Medical Research Council), National Institute of Health Research, and the 
Wellcome Trust through the COVID-19 Therapeutics Accelerator.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Thrombosis is a key feature of severe COVID-19, with 
5–30% of hospitalised patients (depending on illness 
severity) having a major venous thromboembolic event 
(mostly pulmonary embolism) and up to 3% of patients 
having an arterial thromboembolic event, particularly 
myocardial infarction and ischaemic stroke.1,2 The risk of 
thromboembolic complications is reported to be higher 
in COVID-19 than in other acute medical illnesses and 
viral respiratory infections, and is associated with worse 
prognosis.3,4
Anti-platelet therapy might have beneficial effects in 
severe COVID-19 through several mechanisms, including 
inhibition of platelet aggregation, reduction of platelet-
derived inflammation, and blocking of thrombogenic 
neutrophil extracellular traps.5 Aspirin is an affordable, 
globally available drug which at low doses irreversibly 
inhibits the cyclooxygenase-1 enzyme, which is responsible 
for production of thromboxane A2 and proinflammatory 
prostaglandins. Aspirin can reduce both arterial and 
venous thrombotic events and has been shown to prevent 
in-vitro hyperactivity in platelets from patients with 
SARS-CoV-2.6,7 Existing evidence from randomised trials 
has shown that 75–150 mg aspirin per day is as effective as 
higher doses in preventing cardiovascular events.6
Seven clinical trials of aspirin in COVID-19 are 
registered, but none have yet reported on the effect of 
aspirin therapy in COVID-19. Here we report the results 
of a large randomised controlled trial of aspirin in 
patients hospitalised with COVID-19.
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Methods
Study design and participants
The Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial is an investigator-initiated, indi-
vidually randomised, controlled, open-label, platform 
trial to evaluate the effects of potential treatments in 
patients hospitalised with COVID-19. Details of the trial 
design and results for other treatments evaluated 
(including lopinavir–ritonavir, hydroxychloroquine, 
dexamethasone, azithromycin, tocilizumab, convalescent 
plasma, and colchicine) have been published pre-
viously.8–14 Aspirin comparison was conducted at 
167  hospitals in the UK, two hospitals in Indonesia, and 
two hospitals in Nepal (appendix pp 5–26), and is 
supported in the UK by the National Institute for Health 
Research Clinical Research Network. The trial was 
coordinated by the Nuffield Department of Population 
Health at the University of Oxford (Oxford, UK), the trial 
sponsor. The trial was done in accordance with the 
principles of the International Conference on 
Harmonisation Good Clinical Practice guidelines and 
approved by the UK Medicines and Healthcare products 
Regulatory Agency and the Cambridge East Research 
Ethics Committee (reference 20/EE/0101). The protocol, 
statistical analysis plan, and additional information are 
available on the study website.
Patients admitted to hospital were eligible for the trial 
if they had clinically suspected or laboratory-confirmed 
SARS-CoV-2 infection and no medical history that might, 
in the opinion of the attending clinician, put the patient 
at substantial risk if they were to participate in the trial. 
Children younger than 18 years were not eligible for 
random assignment to aspirin. Patients with known 
hypersensitivity to aspirin, a recent history of major 
bleeding, or currently receiving aspirin or another anti-
platelet treatment were excluded. Written informed 
consent was obtained from all patients, or a legal 
representative if they were too unwell or unable to 
provide consent.
Randomisation and masking
Baseline data were collected using a web-based case-
report form that included demographics, amount of 
respiratory support, major comorbidities, suitability of 
the study treatment for a particular patient, and treatment 
availability at the study site (appendix pp 33–34). Eligible 
and consenting adult patients were assigned in a 1:1 ratio 
to either usual standard of care or usual standard of care 
plus aspirin using web-based simple (unstratified) 
randomisation with allocation concealed until after 
randomisation (appendix p 30). For some patients, 
aspirin was unavailable at the hospital at the time of 
enrolment or was considered by the managing physician 
to be either definitely indicated or definitely con-
traindicated. These patients were excluded from the 
randomised comparison between usual care plus aspirin 
and usual care alone.
As a platform trial, and in a factorial design, patients 
could be simultaneously randomly assigned to the 
following other treatment groups: azithromycin, col-
chicine, or dimethyl fumarate versus usual care; conva-
lescent plasma or casirivimab and imdevimab versus 
usual care; and baricitinib versus usual care (appendix 
p 30). Until Jan 24, 2021, the trial also allowed a 
subsequent randomisation for patients with progressive 
COVID-19 (evidence of hypoxia and a hyperinflammatory 
Research in context
Evidence before this study
Patients with COVID-19 are at risk of thromboembolic 
complications. Anti-thrombotic therapies such as aspirin might 
be useful to prevent vascular events and improve outcomes. 
We searched MEDLINE, Embase, bioRxiv, medRxiv, and the WHO 
International Clinical Trials Registry Platform (ICTRP), from 
Sept 1, 2019, up to Feb 25, 2021, for completed published 
randomised clinical trials establishing the effect of aspirin in 
patients with COVID-19. For MEDLINE and Embase, we used the 
search terms “Coronavirus infections/”, “SARS-CoV-2.mp.”, 
“Coronavirus/” or “CORONAVIRUS.mp”, “COVID.mp.”, 
“COVID-19.mp.”, “2019-nCoV.mp.”, “COVID19.mp”, 
“SARSCoV2.mp”, or “SARS-Cov2.mp” and “aspirin.mp”, 
“aspirin/”, or “acetylsalicylic acid/”, filtered by randomised 
controlled trials according to validated filters. For medRxiv and 
bioRxiv, we used the search term “aspirin”. We identified no 
published randomised controlled trials assessing aspirin as a 
treatment for patients with COVID-19 in any clinical scenario. 
The WHO ICTRP database listed seven ongoing randomised 
trials of aspirin, two in outpatients and five in inpatients.
Added value of this study
To the best of our knowledge, the Randomised Evaluation of 
COVID-19 Therapy (RECOVERY) trial is the first randomised 
controlled trial to report on the effect of aspirin as a 
treatment for hospitalised patients with COVID-19. 
We found that in 14 892 adults hospitalised with COVID-19, 
150 mg aspirin did not reduce 28 day mortality, and among 
patients who were not receiving invasive mechanical 
ventilation at randomisation, did not reduce the probability 
of progression to the composite outcome of invasive 
mechanical ventilation or death. Allocation to aspirin was 
associated with an increase in the rate of being discharged 
alive within 28 days, but the magnitude of the effect was 
small (1% absolute difference).
Implications of all the available evidence
Our findings do not support the use of aspirin as a treatment 
for hospitalised patients with COVID-19.
For more on the RECOVERY trial 
see www.recoverytrial.net
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state) to tocilizumab versus usual care. Participants and 
local study staff were not masked to the allocated 
treatment. The trial steering committee, investigators, 
and all other individuals involved in the trial were masked 
to aggregated outcome data during the trial.
Procedures
Patients allocated to aspirin received 150 mg by mouth 
(or nasogastric tube) or by rectum every day until 
discharge. The 150 mg dose of aspirin once per day was 
chosen to ensure sufficient inhibition of platelet 
cyclooxygenase-1 activity in all participants, including 
those who were overweight.15
A single online follow-up form was completed when 
participants were discharged, had died, or 28 days after 
randomisation, whichever occurred earliest (appendix 
pp 35–41). We recorded information on adherence to 
allocated study treatment, receipt of other COVID-19 
treatments, duration of admission, receipt of respiratory 
or renal support, and vital status (including cause of 
death). In addition, in the UK, we obtained routine 
health-care and registry data, including information on 
vital status (with date and cause of death), discharge 
from hospital, receipt of respiratory support, or renal 
replacement therapy.
Outcomes
Outcomes were assessed 28 days after randomisation, 
with further analyses specified at 6 months. The primary 
outcome was all-cause mortality. Secondary outcomes 
were time to discharge from hospital, and, among 
patients not on invasive mechanical ventilation at 
randomisation, progression to invasive mechanical venti-
lation (including extracorporeal membrane oxygenation) 
or death. Prespecified subsidiary clinical outcomes were 
use of non-invasive respiratory support, time to 
successful cessation of invasive mechanical ventilation 
(defined as cessation of invasive mechanical ventilation 
within, and survival to, 28 days), use of renal dialysis or 
haemofiltration, cause-specific mortality, major bleeding 
events (defined as intracranial bleeding or bleeding 
requiring transfusion, endoscopy, surgery, or vasoactive 
drugs), thrombotic events (defined as acute pulmonary 
embolism, deep-vein thrombosis, ischaemic stroke, 
myocardial infarction, or systemic arterial embolism) 
and major cardiac arrhythmias. Information on 
suspected serious adverse reactions was collected in 
an expedited fashion to comply with regulatory 
requirements.
Statistical analysis
We did an intention-to-treat comparison between patients 
randomly assigned to aspirin and patients randomly 
assigned to usual care but for whom aspirin was both 
available and suitable as a treatment. For the primary 
outcome of 28 day mortality, the observed log rank minus 
the expected statistic and its variance were used to both 
test the null hypothesis of equal survival curves (ie, the 
log-rank test) and to calculate the one-step estimate of the 
average mortality rate ratio. We constructed Kaplan-Meier 
survival curves to display cumulative mortality over the 
28 day period. We used the same method to analyse time 
to hospital discharge and successful cessation of invasive 
mechanical ventilation, with patients who died in hospital 
censored on day 29. Median time to discharge was derived 
from Kaplan-Meier estimates. For the prespecified 
composite secondary outcome of progression to invasive 
mechanical ventilation or death within 28 days (among 
those not receiving invasive mechanical ventilation at 
randomisation), and the subsidiary clinical outcomes of 
receipt of ventilation and use of haemodialysis or 
haemofiltration, the precise dates were not available, and 
so the risk ratio was estimated instead.
Prespecified subgroup analyses (defined by charac-
teristics at randomisation, including age, sex, ethnicity, 
amount of respiratory support, days since symptom 
onset, and use of corticosteroids) were done for the 
primary outcome. We did a sensitivity analysis restricting 
analysis of the primary outcome to patients with a 
positive PCR test for SARS-COV-2. In addition, we did 
post-hoc exploratory analyses of the primary and 
secondary outcomes by venous thromboprophylaxis 
treatment at randomisation. Observed effects within 
subgroup categories were compared using a χ² test 
for heterogeneity or trend, in accordance with the 
prespecified analysis plan (appendix p 99).
Estimates of rate and risk ratios are shown with 
95% CIs. All p values are two sided and are shown 
without adjustment for multiple testing. The full 
database is held by the study team that collected the data 
from the study sites and did the analyses at the Nuffield 
Department of Population Health, University of Oxford 
(Oxford, UK).
As stated in the protocol, appropriate sample sizes 
could not be estimated when the trial was being planned 
at the start of the COVID-19 pandemic (appendix p 33). 
As the trial progressed, the trial steering committee, 
whose members were unaware of the results of the trial 
comparisons, established that sufficient patients should 
be enrolled to provide at least 90% power at a two-sided 
significance level of 1% to detect a clinically relevant 
proportional reduction in 28 day mortality of 12·5% 
between the two groups. Consequently, on March 21, 2021, 
the steering committee, masked to the results, closed 
recruitment to the aspirin comparison as sufficient 
patients had been recruited.
Analyses were done using SAS version 9·4 and 
R version 4·0·3. The trial is registered with ISRCTN 
(50189673) and ClinicalTrials.gov (NCT04381936).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
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Results
Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 
22 560 patients enrolled into the RECOVERY trial were 
eligible to be randomly allocated to aspirin (ie, aspirin 
was available in the hospital at the time and the attending 
clinician was of the opinion that the patient had no 
known indication for or contraindication to aspirin; 
figure 1). Baseline characteristics of the patients are 
presentend (table 1). 7351 patients were randomly 
allocated to usual care plus aspirin and 7541 were 
randomly allocated to usual care alone. The mean age of 
study participants in this comparison was 59·2 years 
(SD 14·2) and the median time since symptom onset was 
9 days (IQR 6–12 days; appendix p 45). At randomisation, 
5035 (34%) patients were receiving thromboprophylaxis 
with higher-dose low molecular weight heparin (LMWH), 
8878 (60%) patients were receiving standard-dose 
LMWH, and 979 (7%) patients were not receiving 
thromboprophylaxis (appendix p 54).
The follow-up form was completed for 7290 (99%) of 
7351 participants in the aspirin group and 7457 (99%) of 
7541 participants in the usual care group. Among 
participants with a completed follow-up form, 6587 (90%) 
patients allocated to aspirin received at least one dose of 
aspirin and 210 (3%) allocated to usual care received at 
least one dose of aspirin (figure 1; appendix p 46). Of the 
6587 participants allocated to aspirin that received at least 
one dose of aspirin, 5040 (77%) received aspirin on most 
days following randomisation (≥90% of the days from 






Age (years) 59·2 (14·1) 59·3 (14·3)
<70 5658 (77%) 5786 (77%)
70–79 1163 (16%) 1165 (15%)
≥80 530 (7%) 590 (8%)
Sex
Male 4570 (62%) 4631 (61%)
Female* 2781 (38%) 2910 (39%)
Ethnicity
White 5474 (74%) 5655 (75%)
Black, Asian, and minority 
ethnic
1176 (16%) 1202 (16%)
Unknown 701 (10%) 684 (9%)
Number of days since symptom 
onset
9 (7–12) 9 (6–12)
Number of days since 
hospitalisation
1 (1–3) 2 (1–3)
Respiratory support received
None or simple oxygen 4936 (67%) 5036 (67%)
Non-invasive ventilation 2057 (28%) 2133 (28%)
Invasive mechanical 
ventilation
358 (5%) 372 (5%)
Biochemistry
C-reactive protein, mg/L 88 (47–146) 91 (47–150)
Creatinine, µmol/L 76 (63–93) 76 (62–92)
D-dimer, ng/mL 475 (205–1088) 489 (210–1083)
Previous diseases
Diabetes 1588 (22%) 1659 (22%)
Heart disease 776 (11%) 788 (10%)
Chronic lung disease 1425 (19%) 1411 (19%)
Tuberculosis 20 (<1%) 21 (<1%)
HIV 25 (<1%) 21 (<1%)
Severe liver disease† 67 (1%) 53 (1%)
Severe kidney impairment‡ 214 (3%) 251 (3%)
Any of the previous diseases 3154 (43%) 3247 (43%)
Use of corticosteroids
Yes 6906 (94%) 7109 (94%)
No 441 (6%) 425 (6%)
Data missing 4 (<1%) 7 (<1%)
SARS-CoV-2 test result
Positive 7140 (97%) 7327 (97%)
Negative 87 (1%) 86 (1%)
Unknown 124 (2%) 128 (2%)
Data are n (%), mean (SD), or median (IQR). *Includes 58 pregnant women. 
†Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular 
filtration rate lower than 30 mL/min per 1·73 m².
Table 1: Baseline characteristics
Figure 1: Trial profile
 Aspirin unavailable and aspirin unsuitable groups are not mutually exclusive. *Number recruited overall during the 
period that adult participants could be recruited into the aspirin comparison. †Includes 379 (5%) of 7351 patients 
in the aspirin group and 407 (5%) of 7541 patients in the usual care group allocated to tocilizumab.
7541 assigned usual care alone
7457 with completed 
follow-up form at the  
time of analysis, of 
which 210 received 
aspirin
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randomisation, whichever was earlier). Use of other 
treatments for COVID-19 was similar among participants 
allocated to aspirin and among those allocated to usual 
care, with nearly 90% receiving a corticosteroid, about a 
quarter receiving remdesivir, and an eighth receiving 
tocilizumab (appendix p 46).
Primary and secondary outcome data were known for 
99% of randomly assigned patients. We observed no 
significant difference in the proportion of patients who 
met the primary outcome of 28 day mortality between 
the two randomised groups (1222 [17%] of 7351 patients 
in the aspirin group vs 1299 [17%] of 7541 patients in the 
usual care group; rate ratio 0·96, 95% CI 0·89–1·04; 
p=0·35; figure 2, table 2). The rate ratio was similar 
across all prespecified subgroups (figure 3). In an 
exploratory analysis restricted to the 14 467 (97%) of 
14 892 patients with a positive SARS-CoV-2 test result, the 
result was virtually identical (rate ratio 0·96, 95% CI 
0·89–1·04; p=0·31).
Allocation to aspirin was associated with a reduction of 
1 day in median time until discharge alive from hospital 
compared with usual care and an increased rate of 
discharge alive within 28 days (table 2). Among patients 
not on invasive mechanical ventilation at baseline, the 
number of patients progressing to the prespecified 
composite secondary outcome of invasive mechanical 
ventilation or death among those allocated to aspirin was 
similar to that among those allocated to usual care 
(table  2). There was no evidence that the effect of 
allocation to aspirin versus usual care on time until 
discharge alive from hospital, or invasive mechanical 
ventilation or death differed between the prespecified 
subgroups of patients (appendix pp 52–53). In a post-hoc 
exploratory analysis, there was no evidence that the effect 
of allocation to aspirin versus usual care on the primary 
and secondary outcomes differed by use of LMWH at 
randomisation (appendix p 54).
We found no significant differences in the 
prespecified subsidiary clinical outcomes of cause-
specific mortality (appendix p 47), use of ventilation, 
successful cessation of invasive mechanical ventilation, 
or receipt of renal dialysis or haemofiltration (table 2). 
As expected with the use of aspirin, the incidence of 
thrombotic events was lower (4·6% vs 5·3%, absolute 
difference –0·6%, SE 0·4%) and the incidence of major 
bleeding events was higher (1·6% vs 1·0%, absolute 
difference 0·6%, SE 0·2%) in the aspirin group 
(appendix p 48) than in the usual care group. The 
incidence of new cardiac arrhythmias was similar in 
the two groups (appendix p 49). There were 18 reports 
of a serious adverse event believed to be related to 
aspirin, all of which were due to haemorrhagic events 
(appendix p 50).
Discussion
In this large, randomised trial involving more than 
14 000 patients and more than 2000 deaths, allocation to 
aspirin was not associated with reductions in mortality 
or, among patients not on invasive mechanical ventilation 
at baseline, the risk of progressing to the composite 
endpoint of invasive mechanical ventilation or death. 
Allocation to aspirin was, however, associated with a 
small increase in the rate of being discharged from 
hospital alive within 28 days. These results were 
consistent across the prespecified subgroups of age, sex, 
ethnicity, duration of symptoms before randomisation, 
amount of respiratory support at randomisation, and use 
of corticosteroids.








































Treatment allocation RR (95% CI) p value
Aspirin (n=7351) Usual care (n=7541)
Primary outcome
28 day mortality 1222 (17%) 1299 (17%) 0·96 (0·89–1·04) 0·35
Secondary outcomes
Median time to being discharged 
alive (IQR), days
8 (5 to >28) 9 (5 to >28) ·· ··
Discharged from hospital within 
28 days
5496 (75%) 5548 (74%) 1·06 (1·02–1·10) 0·0062
Receipt of invasive mechanical 
ventilation or death*
1473/6993 (21%) 1569/7169 (22%) 0·96 (0·90–1·03) 0·23
Invasive mechanical ventilation 772/6993 (11%) 829/7169 (12%) 0·95 (0·87–1·05) 0·32
Death 1076/6993 (15%) 1141/7169 (16%) 0·97 (0·90–1·04) 0·39
Subsidiary clinical outcomes
Use of ventilation 1131/4936 (23%) 1198/5036 (24%) 0·96 (0·90–1·03) 0·30
Non-invasive ventilation 1101/4936 (22%) 1162/5036 (23%) 0·97 (0·90–1·04) 0·36
Invasive mechanical ventilation 296/4936 (6%) 325/5036 (6%) 0·93 (0·80–1·08) 0·35
Successful cessation of invasive 
mechanical ventilation
135/358 (38%) 135/372 (36%) 1·08 (0·85–1·37) 0·54
Renal replacement therapy 273/7291 (4%) 282/7480 (4%) 0·99 (0·84–1·17) 0·93
RR=rate ratio for the outcomes of 28-day mortality and hospital discharge, and rate ratio for the outcome of receipt of 
invasive mechanical ventilation or death (and its subcomponents).  *Analyses exclude those on invasive mechanical 
ventilation at randomisation.
Table 2: Effect of allocation to aspirin on key study outcomes
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As expected, allocation to aspirin was associated with 
an increased risk of major bleeding and a decreased risk 
of thromboembolic complications, such that for every 
1000 patients treated with aspirin, approximately six more 
patients would have a major bleeding event and 
approximately six fewer patients would have a thrombo-
embolic event. The rate of reported thromboembolic 
events in our study population was low (5·3% in the 
usual care group) in comparison with previous reports.1,2 
This finding could be because participants were not 
systematically screened for thromboembolic events, 
could be related to the widespread use of corticosteroids 
in the trial population, resulting in reduced thrombo-
inflammatory stimulus, or could be because of the 
exclusion of patients already receiving aspirin due to 
previous cardiovascular disease. It is possible that aspirin 
might have a more meaningful benefit in populations 
with a higher thrombotic risk, although there would also 
probably be a corresponding increase in bleeding risk.16
The pathogenesis of thromboembolism in COVID-19 
is likely to be multifactorial. Coagulopathy is common 
in severe COVID-19 and is associated with an 
inflammatory state, neutrophil extracellular traps, and 
poor outcomes.2,17–21 Platelet activation is increased as a 
result (and potentially by direct interaction with the 
virus), amplifying inflammation locally and triggering 
immunothrombosis.22,23 In addition, SARS-CoV-2 infect-
ion can cause inflammation, dysfunction, and 
disruption of the vascular endothelium in multiple 
organs, potentially via direct entry through the 
angiotensin-converting enzyme 2 receptor.24–26 The 
resulting endothelial injury and tissue factor exposure 
promote thrombosis in the pulmonary circulation and 
other vascular beds, with microangiopathy and alveolar 
capillary occlusion contributing to the diffuse alveolar 
damage and hypoxaemia seen in COVID-19.25,27 
Furthermore, in autopsy studies pulmonary micro-
thrombi are nine times more frequent in patients with 
COVID-19 than patients with influenza.25
A large number of randomised controlled trials of 
antithrombotic therapy in COVID-19 are registered, 
including trials of therapeutic doses of heparin, direct-
acting oral anticoagulants, anti-platelet agents, serine 
protease inhibitors, and thrombolytics.28 In patients who 
Figure 3: Effect of allocation to aspirin on 28 day mortality by baseline characteristics
Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines 
through them correspond to 95% CIs. The ethnicity, days since onset, and use of corticosteroids subgroups exclude patients with missing data, but these patients are 
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are critically ill, the INSPIRATION, REMAP-CAP, 
ACTIV-4a, and ATTAC trials did not report a benefit in 
clinical outcomes from therapeutic anticoagulation.29,30 
Similarly, preliminary results from the COALIZAO-
ACTION trial31 did not show a benefit from therapeutic 
anticoagulation (either heparin or rivaroxaban) in a 
combined endpoint of mortality, successful discharge, or 
need for oxygen in hospitalised patients with elevated 
D-dimers. However, the REMAP-CAP, ACTIV-4a, and 
ATTAC investigators have reported that in patients 
not critically ill with COVID-19, compared with 
thromboprophylaxis doses heparin at therapeutic doses 
was associated with an absolute increase of 4·6% 
(95% credible interval 0·7–8·1) in the proportion of 
participants surviving to hospital discharge without 
receipt of organ support during the first 21 days.32
Although there are no other published randomised trial 
data on the use of aspirin in COVID-19, the REMAP-CAP, 
ACTIV-4a, and ATTAC report does suggest that 
antithrombotic therapy might be important in some 
patients.32 The absence of meaningful benefit from aspirin 
in our trial could be because anti-platelet therapy confers 
no clinically significant additional benefit on top of high 
rates of anti-thrombotic therapy with LMWH and 
corticosteroid treatment diminishing thromboinflam-
matory stimulation. Alternatively, other non-platelet 
pathways leading to thrombosis and alveolar damage might 
be more important determinants of clinical outcomes.
Any potential benefit of antithrombotic therapies in 
patients with COVID-19 could also depends on timing of 
treatment initiation, especially if thrombi have already 
developed by the time of admission.33 Thromboembolic 
events and microthrombi are common in patients with 
COVID-19 on either prophylactic or therapeutic 
anticoagulation.34 The apparent absence of benefit in 
INSPIRATION and the REMAP-CAP, ACTIV-4a, and 
ATTAC severe disease cohorts suggests that these 
patients might have passed the point at which any benefit 
from therapeutic anticoagulation could be gained.29,30 
Although we found no evidence of heterogeneity on the 
basis of duration of symptoms, baseline disease severity, 
or background thrombotic prophylaxis regimen, ongoing 
trials of aspirin in ambulatory populations and those 
exploring more potent anti-platelet inhibition and 
fibrinolysis should provide further insights.
The strengths of this trial included that it was 
randomised, had a large sample size, broad eligibility 
criteria, and 99% of patients were followed up for the 
primary outcome. The trial also had some limitations. 
Detailed information on radiological or physiological 
outcomes was not collected. Although this randomised 
trial is open label (ie, participants and local hospital staff 
are aware of the assigned treatment), the primary and 
secondary outcomes are unambiguous and were 
ascertained without bias through linkage to routine 
health records. However, it cannot be excluded that 
reporting of thromboembolic and bleeding events might 
have been influenced by knowledge of treatment 
allocation. Nevertheless, the proportional effects of 
aspirin on these events were very similar to those 
reported in previous large clinical trials of aspirin in 
people with previous cardiovascular disease.6
The RECOVERY trial only studied patients with 
COVID-19 who were hospitalised, and therefore is not 
able to provide evidence on the safety and efficacy of 
aspirin used in other patient groups. Further studies to 
identify the safety and efficacy of aspirin in patients with 
COVID-19 who are not hospitalised are needed and are 
ongoing.
In summary, the results of this large, randomised trial 
do not support the addition of aspirin to standard 
thromboprophylaxis or therapeutic anticoagulation in 
patients hospitalised with COVID-19.
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